AB Science Completes EUR 1.8 Million Private Placement

AB Science S.A. has successfully raised EUR 1.8 million through a private placement with select investors. This capital increase was executed without the need for a prospectus approved by the French Financial Market Authority. The proceeds will primarily support the clinical development of AB8939, focusing on oncology.

The placement involved issuing 1,538,463 new shares with attached share warrants, at a price of EUR 1.17 per unit, reflecting a 24.8% discount on the average market price. Should all warrants be exercised, an additional EUR 2.8 million could be raised, potentially expanding the company's capital to 60,907,220 shares.

The new shares are set for trading on Euronext Paris by May 22, 2025, with a 45-day lock-up period for the company and a 90-day period for its officers. AB Science's share dilution effects are noted for non-participating shareholders.